(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 June 2015 (11.06.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/085172 A3

(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/US2014/068795

(22) International Filing Date:
5 December 2014 (05.12.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/913,003	6 December 2013 (06.12.2013)	US
61/947,963	4 March 2014 (04.03.2014)	US
61/990,621	8 May 2014 (08.05.2014)	US
62/061,050	7 October 2014 (07.10.2014)	US
62/064,413	15 October 2014 (15.10.2014)	US
62/077,835	10 November 2014 (10.11.2014)	US
62/087,111	3 December 2014 (03.12.2014)	US

(71) Applicant: **CELGENE CORPORATION** [US/US]; 86 Morris Avenue, Summit, NJ 07901 (US).

(72) Inventors: **TROTTER, Matthew William, Burnell**; Calle Alcazar 43, E-41807 Espartinas, Sevilla (ES). **HAGNER, Patrick**; 22 Oakwood Trail, Sparta, NJ 07871 (US). **HAVENS, Courtney, G.**; 11 Catherine Lane, Morristown, NJ 07960 (US). **CHOPRA, Rajesh**; 54 Eggers Court, Summit, NJ 07901 (US). **GANDHI, Anita**; 37 Stirling Road, Bernardsville, NJ 07924 (US). **KLIPPEL, Anke**; 21 Moss Avenue, Westfield, NJ 07090 (US). **WANG, Maria, Yinglin**; 7285 Calabria Ct., #20, San Diego, CA 92122 (US). **BREIDER, Mike**; 1833 Somerset Avenue, Cardiff-by-the-sea, CA 92007 (US). **COUTO, Suzana, Sturlini**; 5816 Cactus Way, La Jolla, CA 92037 (US). **REN, Yan**; 6310 Sagebrush Bend Way, San Diego, CA 92130 (US). **HOLLENBACH, Paul**; 20793 Glenwood Drive, Castro Valley, CA 94552 (US). **MACBETH, Kyle**; 1356 Stevenson Street, San Francisco, CA 94103 (US).

(74) Agents: **WEISSER, Tamera** et al.; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:
12 November 2015

(54) Title: METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS



Figure 1A

(57) Abstract: Provided herein, in some embodiments, are methods of using certain cereblon- associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.

WO 2015/085172 A3